IMU Biosciences

Name: IMU Biosciences
Brand: IMU Biosciences

Mapping the immune system across health and disease to power precision medicine

Est 2019

LinkedIn 7K|Website|FTEs 25|HQ London, United Kingdom

01Competitive Landscape

Narrative analysis

- IMU’s likely differentiator is a combined offering of immune profiling, signature discovery, and a proprietary atlas. If validated, this combination may be valuable for organizations that lack in-house capability to operationalize high-dimensional immunophenotyping. - Alternatives can be stronger in specific areas: - Instrument vendors (e.g., 10x Genomics) provide standard tools and a large community knowledge base. - Specialized immunogenomics providers (e.g., Adaptive) may be preferable for receptor-sequencing–centric questions. - Large CROs may offer more predictable delivery at scale, standardized operations, and extensive regulatory documentation. **Sources used for IMU’s positioning (for comparison):** - Official vendor documentation and product overview pages - Industry press coverage and business news reporting on CytAtlas and its claimed cell-type / immune-signature coverage

	IMU Biosciences (IMU® Platform / CytAtlas®)	Adaptive Biotechnologies (immune repertoire)	10x Genomics (single-cell tools)
Starting Price	Not public; partnership/SOW based	Not public for many offerings; mix of products and services	Published instrument/consumables pricing varies by product; generally capital equipment plus consumables
Most Applicable For	Systems-level immune profiling and signature discovery tied to curated cohorts; translational programs needing deep immunophenotyping	TCR/BCR repertoire-centric immune insights, MRD/immune monitoring programs where repertoire is central	Laboratories seeking in-house single-cell experiments and control of wet-lab pipelines
Key Strength	Vendor-reported: high-resolution immune cell subset quantification; proprietary immune atlas and ML analytics	Scale and maturity in repertoire sequencing and biopharma relationships	Widely adopted tooling ecosystem; supports broad discovery workflows
Key Weakness	Limited public independent validation; scarce third-party reviews; pricing opacity; dependence on centralized services	May be less focused on full systems cytometry phenotype for some applications	Customers must develop internal analytics and workflows; not a turnkey signature product

01Competitive Landscape

Narrative analysis

IMU’s likely differentiator is a combined offering of immune profiling, signature discovery, and a proprietary atlas. If validated, this combination may be valuable for organizations that lack in-house capability to operationalize high-dimensional immunophenotyping.
Alternatives can be stronger in specific areas:
- Instrument vendors (e.g., 10x Genomics) provide standard tools and a large community knowledge base.
- Specialized immunogenomics providers (e.g., Adaptive) may be preferable for receptor-sequencing–centric questions.
- Large CROs may offer more predictable delivery at scale, standardized operations, and extensive regulatory documentation.

Sources used for IMU’s positioning (for comparison):

Official vendor documentation and product overview pages
Industry press coverage and business news reporting on CytAtlas and its claimed cell-type / immune-signature coverage

	IMU Biosciences (IMU® Platform / CytAtlas®)	Adaptive Biotechnologies (immune repertoire)	10x Genomics (single-cell tools)
Starting Price	Not public; partnership/SOW based	Not public for many offerings; mix of products and services	Published instrument/consumables pricing varies by product; generally capital equipment plus consumables
Most Applicable For	Systems-level immune profiling and signature discovery tied to curated cohorts; translational programs needing deep immunophenotyping	TCR/BCR repertoire-centric immune insights, MRD/immune monitoring programs where repertoire is central	Laboratories seeking in-house single-cell experiments and control of wet-lab pipelines
Key Strength	Vendor-reported: high-resolution immune cell subset quantification; proprietary immune atlas and ML analytics	Scale and maturity in repertoire sequencing and biopharma relationships	Widely adopted tooling ecosystem; supports broad discovery workflows
Key Weakness	Limited public independent validation; scarce third-party reviews; pricing opacity; dependence on centralized services	May be less focused on full systems cytometry phenotype for some applications	Customers must develop internal analytics and workflows; not a turnkey signature product

IMU Biosciences

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map